

# Pramodini B Kale-Pradhan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6572910/publications.pdf>

Version: 2024-02-01

49  
papers

1,017  
citations

516215

16  
h-index

433756

31  
g-index

49  
all docs

49  
docs citations

49  
times ranked

1621  
citing authors

#	ARTICLE	IF	CITATIONS
1	Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Review of Clinical Pharmacology, 2012, 5, 337-344.	1.3	116
2	Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Review of Clinical Pharmacology, 2013, 6, 443-451.	1.3	101
3	Effect of Bariatric Surgery on Hypertension. Annals of Pharmacotherapy, 2014, 48, 674-682.	0.9	95
4	Role of <i>Lactobacillus</i> in the Prevention of Antibiotic-Associated Diarrhea: A Meta-analysis. Pharmacotherapy, 2010, 30, 119-126.	1.2	76
5	Is the Combination of Piperacillin-Tazobactam and Vancomycin Associated with Development of Acute Kidney Injury? A Meta-analysis. Pharmacotherapy, 2016, 36, 1217-1228.	1.2	71
6	Treating Bugs with Bugs: The Role of Probiotics as Adjunctive Therapy for Helicobacter pylori. Annals of Pharmacotherapy, 2011, 45, 960-966.	0.9	50
7	Prevention of Postoperative Nausea and Vomiting. Annals of Pharmacotherapy, 2007, 41, 68-78.	0.9	48
8	A review of infliximab use in ulcerative colitis. Clinical Therapeutics, 2008, 30, 223-230.	1.1	47
9	Estimating Creatinine Clearance: A Meta-analysis. Pharmacotherapy, 2011, 31, 658-664.	1.2	47
10	Esomeprazole for Acid Peptic Disorders. Annals of Pharmacotherapy, 2002, 36, 655-663.	0.9	38
11	Comparative Efficacy of Echinocandins and Nonechinocandins for the Treatment of <i>Candida parapsilosis</i> Infections: A Meta-analysis. Pharmacotherapy, 2010, 30, 1207-1213.	1.2	32
12	New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir. Expert Review of Clinical Pharmacology, 2016, 9, 287-302.	1.3	31
13	Effectiveness of Probiotics in the Treatment of Irritable Bowel Syndrome. Pharmacotherapy, 2008, 28, 496-505.	1.2	24
14	Teduglutide for the Treatment of Short Bowel Syndrome. Annals of Pharmacotherapy, 2014, 48, 1209-1213.	0.9	22
15	Combination of Vancomycin or Daptomycin and Beta-lactam Antibiotics: A Meta-analysis. Pharmacotherapy, 2020, 40, 648-658.	1.2	19
16	Pancreatic Enzyme Products: Digesting the Changes. Annals of Pharmacotherapy, 2011, 45, 658-666.	0.9	18
17	Impact of Pharmacist Involvement in Heart Failure Transition of Care. Annals of Pharmacotherapy, 2020, 54, 239-246.	0.9	18
18	The role of antimicrobials in Crohn's disease. Expert Review of Gastroenterology and Hepatology, 2013, 7, 281-288.	1.4	14

#	ARTICLE	IF	CITATIONS
19	The Efficacy of Extended-Interval Dosing of Omeprazole in Keeping Gastroesophageal Reflux Disease Patients Symptom Free. <i>Annals of Pharmacotherapy</i> , 1999, 33, 638-641.	0.9	13
20	Roflumilast in the management of chronic obstructive pulmonary disease. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 2087-2095.	0.5	12
21	Effects of proton pump inhibitors on vitamin B12. <i>Maturitas</i> , 2014, 79, 1-2.	1.0	12
22	Fluoroquinolone Sequential Therapy for <i>Helicobacter pylori</i> : A Meta-analysis. <i>Pharmacotherapy</i> , 2015, 35, 719-730.	1.2	12
23	Biologic-Induced Infections in Inflammatory Bowel Disease: The TNF- $\alpha$ Antagonists. <i>Annals of Pharmacotherapy</i> , 2018, 52, 571-579.	0.9	12
24	Adherence to GOLD Guidelines in the Inpatient COPD Population. <i>Journal of Pharmacy Practice</i> , 2018, 31, 29-33.	0.5	12
25	Multi-Matrix System Mesalamine: To Use or Not To Use. <i>Annals of Pharmacotherapy</i> , 2008, 42, 265-269.	0.9	11
26	Novel Therapies for Crohn's Disease: Focus on Immunomodulators and Antibiotics. <i>Annals of Pharmacotherapy</i> , 2006, 40, 1804-1813.	0.9	10
27	Tegaserod for Constipation-Predominant Irritable Bowel Syndrome. <i>Pharmacotherapy</i> , 2007, 27, 267-277.	1.2	10
28	Combination of arginine and omega-3 fatty acids enteral nutrition in critically ill and surgical patients: a meta-analysis. <i>Expert Review of Clinical Pharmacology</i> , 2010, 3, 459-469.	1.3	8
29	Meta-Analysis. <i>Journal of Pharmacy Technology</i> , 2016, 32, 65-70.	0.5	6
30	Treatment and recurrence management of staphylococcal infections: community-acquired MRSA. <i>Expert Review of Anti-Infective Therapy</i> , 2008, 6, 909-915.	2.0	5
31	Enteral Nutrition in Patients with Pancreatitis. <i>Pharmacotherapy</i> , 1999, 19, 1036-1041.	1.2	4
32	Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 391-400.	1.3	4
33	Vulnerable COPD patients with comorbidities: the role of roflumilast. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 969.	0.9	3
34	Are Blacks at Higher Risk for Vancomycin-Related Acute Kidney Injury?. <i>Journal of Pharmacy Practice</i> , 2020, 33, 592-597.	0.5	3
35	Mechanisms and Potential Roles of Glucose-Lowering Agents in COVID-19: A Review. <i>Annals of Pharmacotherapy</i> , 2021, 55, 1386-1396.	0.9	3
36	Early response of ceftaroline fosamil in the treatment of soft-tissue infections. <i>Expert Review of Clinical Pharmacology</i> , 2012, 5, 509-512.	1.3	2

#	ARTICLE	IF	CITATIONS
37	Adverse drug reactions in drug information databases: does presentation affect interpretation?. Journal of the Medical Library Association: JMLA, 2020, 108, 76-83.	0.6	2
38	Tezepelumab in the Treatment of Uncontrolled Severe Asthma. Annals of Pharmacotherapy, 2023, 57, 62-70.	0.9	2
39	Effect of body weight on aminoglycoside pharmacokinetics in patients with hypoalbuminemia. American Journal of Health-System Pharmacy, 1997, 54, 2201-2203.	0.5	1
40	Clinical Relevance of In Vitro Resistance of Echinocandins: a Focus on Candida parapsilosis. Current Fungal Infection Reports, 2012, 6, 107-112.	0.9	1
41	Dual Versus Mono Bronchodilator Therapy in Moderate to Severe COPD: A Meta-analysis. Annals of Pharmacotherapy, 2020, 54, 1232-1242.	0.9	1
42	Chapter 20: Prebiotics and Probiotics. , 2017, , .		1
43	Vancomycin-Related Renal Insufficiency: Does Race Play a Role?. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
44	1469. Effect of Treatment Duration on Outcomes in Septic Patients Admitted for Urinary Tract Infections from Extended Care Facilities. Open Forum Infectious Diseases, 2019, 6, S536-S537.	0.4	0
45	2008. Outcomes of Patients with Positive Procalcitonin Levels Who Do Not Receive Continued Antibiotics. Open Forum Infectious Diseases, 2019, 6, S674-S674.	0.4	0
46	Chapter 20: Prebiotics and Probiotics. , 2020, , .		0
47	556. Evaluation of Hydroxychloroquine-based Combination Therapies for the Treatment of COVID-19. Open Forum Infectious Diseases, 2020, 7, S343-S343.	0.4	0
48	49. Clinical Utility of Oseltamivir Restriction Policy. Open Forum Infectious Diseases, 2020, 7, S47-S47.	0.4	0
49	1297. Azithromycin vs Beta Lactams in Acute Exacerbations of COPD. Open Forum Infectious Diseases, 2021, 8, S737-S737.	0.4	0